DNA methyltransferase inhibitors: an updated patent review (2012-2015)

References

• Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16:6–21.
   PubMed Web of Science ®Google Scholar
• Riddihough G, Zahn LM. Epigenetics. What is epigenetics? Introduction. Science. 2010;330:611.
   PubMed Web of Science ®Google Scholar
• Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006;5:37–50.
   PubMed Web of Science ®Google Scholar
• Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153:38–55.
   PubMed Web of Science ®Google Scholar
• Plass C. Cancer epigenomics. Hum Mol Genet. 2002;11:2479–2488.
   PubMed Web of Science ®Google Scholar
• Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726–734.
   PubMed Web of Science ®Google Scholar
• Chen QW, Zhu XY, Li YY, et al. Epigenetic regulation and cancer (review). Oncol Rep. 2014;31:523–532.
   PubMed Web of Science ®Google Scholar
• Li L, Chen BF, Chan WY. An epigenetic regulator: methyl-CpG-binding domain protein 1 (MBD1). Int J Mol Sci. 2015;16:5125–5140.
   PubMed Web of Science ®Google Scholar
• Erdmann A, Halby L, Fahy J, et al. Targeting DNA methylation with small molecules: what’s next? J Med Chem. 2015;58:2569–2583.
   PubMed Web of Science ®Google Scholar
• Ye F, Zhang L, Jin L, et al. Repair of methyl lesions in RNA by oxidative demethylation. Med Chem Commun. 2014;5:1797–1803.
   Web of Science ®Google Scholar
• Hake SB, Xiao A, Allis CD. Linking the epigenetic ‘language’ of covalent histone modifications to cancer. Br J Cancer. 2004;90:761–769.
   PubMed Web of Science ®Google Scholar
• Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 2011;1:598–607.
   PubMed Web of Science ®Google Scholar
• Chi P, Allis CD, Wang GG. Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10:457–469.
   PubMed Web of Science ®Google Scholar
• Du J, Johnson LM, Jacobsen SE, et al. DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol. 2015;16:519–532.
   PubMed Web of Science ®Google Scholar
• Hamm CA, Costa FF. The impact of epigenomics on future drug design and new therapies. Drug Discov Today. 2011;16:626–635.
   PubMed Web of Science ®Google Scholar
• Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19:219–220.
   PubMed Web of Science ®Google Scholar
• Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005;74:481–514.
   PubMed Web of Science ®Google Scholar
• Jia D, Jurkowska RZ, Zhang X, et al. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature. 2007;449:248–251.
   PubMed Web of Science ®Google Scholar
• Jin B, Robertson KD. DNA methyltransferases, DNA damage repair, and cancer. Adv Exp Med Biol. 2013;754:3–29.
   PubMed Web of Science ®Google Scholar
• Chedin F. The DNMT3 family of mammalian de novo DNA methyltransferases. Prog Mol Biol Transl Sci. 2011;101:255–285.
   PubMed Web of Science ®Google Scholar
• Robertson KD. DNA methylation, methyltransferases, and cancer. Oncogene. 2001;20:3139–3155.
   PubMed Web of Science ®Google Scholar
• Feng J, Zhou Y, Campbell SL, et al. Dnmt1 and Dnmt3a maintain DNA methylation and regulate synaptic function in adult forebrain neurons. Nat Neurosci. 2010;13:423–430.
   PubMed Web of Science ®Google Scholar
• Medina-Franco JL, Mendez-Lucio O, Duenas-Gonzalez A, et al. Discovery and development of DNA methyltransferase inhibitors using in silico approaches. Drug Discov Today. 2015;20:569–577.
   PubMed Web of Science ®Google Scholar
• Kilgore JA, Du X, Melito L, et al. Identification of DNMT1 selective antagonists using a novel scintillation proximity assay. J Biol Chem. 2013;288:19673–19684.
   PubMed Web of Science ®Google Scholar
• Ceccaldi A, Rajavelu A, Ragozin S, et al. Identification of novel inhibitors of DNA methylation by screening of a chemical library. ACS Chem Biol. 2013;8:543–548.
   PubMed Web of Science ®Google Scholar
• Fagan RL, Wu M, Chedin F, et al. An ultrasensitive high throughput screen for DNA methyltransferase 1-targeted molecular probes. PLoS One. 2013;8:e78752.
   PubMed Web of Science ®Google Scholar
• Tarasova GV, Nayakshina TN, Degtyarev SK. Substrate specificity of new methyl-directed DNA endonuclease GlaI. BMC Mol Biol. 2008;9:7.
   PubMed Web of Science ®Google Scholar
• Gros C, Chauvigne L, Poulet A, et al. Development of a universal radioactive DNA methyltransferase inhibition test for high-throughput screening and mechanistic studies. Nucleic Acids Res. 2013;41:e185.
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148–1159.
   PubMed Web of Science ®Google Scholar
• Gros C, Fahy J, Halby L, et al. DNA methylation inhibitors in cancer: recent and future approaches. Biochimie. 2012;94:2280–2296.
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer. 2008;123:8–13.
   PubMed Web of Science ®Google Scholar
• Fahy J, Jeltsch A, Arimondo PB. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat. 2012;22:1427–1442.
   PubMed Web of Science ®Google Scholar
• Hu J, Chen S, Kong X, et al. Interaction between DNA/histone methyltransferases and their inhibitors. Curr Med Chem. 2015;22:360–372.
   PubMed Web of Science ®Google Scholar
• Chen S, Wang Y, Zhou W, et al. Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening. J Med Chem. 2014;57:9028–9041.
   PubMed Web of Science ®Google Scholar
• Datta J, Ghoshal K, Denny WA, et al. A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 2009;69:4277–4285.
   PubMed Web of Science ®Google Scholar
• Fang MZ, Chen D, Sun Y, et al. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 2005;11:7033–7041.
   PubMed Web of Science ®Google Scholar
• Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63:7563–7570.
   PubMed Web of Science ®Google Scholar
• Fagan RL, Cryderman DE, Kopelovich L, et al. Laccaic acid A is a direct, DNA-competitive inhibitor of DNA methyltransferase 1. J Biol Chem. 2013;288:23858–23867.
   PubMed Web of Science ®Google Scholar
• Zambrano P, Segura-Pacheco B, Perez-Cardenas E, et al. A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer. 2005;5:44.
   PubMed Web of Science ®Google Scholar
• Villar-Garea A, Fraga MF, Espada J, et al. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003;63:4984–4989.
   PubMed Web of Science ®Google Scholar
• Cornacchia E, Golbus J, Maybaum J, et al. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol. 1988;140:2197–2200.
   PubMed Web of Science ®Google Scholar
• Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem. 1988;31:2235–2246.
   PubMed Web of Science ®Google Scholar
• Horton DA, Bourne GT, Smythe ML. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev. 2003;103:893–930.
   PubMed Web of Science ®Google Scholar
• Costantino L, Barlocco D. Privileged structures as leads in medicinal chemistry. Curr Med Chem. 2006;13:65–85.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Sakr WA, Rahman KM. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr Drug Targets. 2010;11:652–666.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Colby DA, Seto S, et al. Total synthesis of vinblastine, vincristine, related natural products, and key structural analogues. J Am Chem Soc. 2009;131:4904–4916.
   PubMed Web of Science ®Google Scholar
• Ikerchem SL. Indole derivatives, pharmaceutical compositions containing such indoles and their use as dna methylation modulators. WO2014072371. 2014.
   Google Scholar
• Glaxosmithkline Intellectual Property Development Limited. New compounds. WO2013062943. 2013.
   Google Scholar
• Isakovic L, Saavedra OM, Llewellyn DB, et al. Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009;19:2742–2746.
   PubMed Web of Science ®Google Scholar
• Glaxosmithkline Intellectual Property Development Limited. Chemical compounds. WO2013062945. 2013.
   Google Scholar
• Pierre Fabre Medicament; Centre National de la Recherche Scientifique (CNRS). Quinazoline derivatives and their use as DNA methyltransferase inhibitors. WO2015040169. 2015.
   Google Scholar
• Ceccaldi A, Rajavelu A, Champion C, et al. C5-DNA methyltransferase inhibitors: from screening to effects on zebrafish embryo development. Chembiochem. 2011;12:1337–1345.
   PubMed Web of Science ®Google Scholar
• Beth Israel Deaconess Medical Center, Inc. Chimeric rna oligonucleotides and uses thereof. US20140171492. 2014.
   Google Scholar
• Beth Israel Deaconess Medical Center, Inc. Chimeric rna oligonucleotides and uses thereof. WO2012142480. 2012.
   Google Scholar
• Metheor Therapeutics Corporation. Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases. WO2014011573. 2014.
   Google Scholar
• Kremer D, Metzger S, Kolb-Bachofen V, et al. Quantitative measurement of genome-wide DNA methylation by a reliable and cost-efficient enzyme-linked immunosorbent assay technique. Anal Biochem. 2012;422:74–78.
   PubMed Web of Science ®Google Scholar
• Lo YM, Wong IH, Zhang J, et al. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 1999;59:3899–3903.
   PubMed Web of Science ®Google Scholar
• New England Biolabs Inc. Dnmt inhibitors. WO2015073360. 2015.
   Google Scholar
• Song J, Rechkoblit O, Bestor TH, et al. Structure of DNMT1-DNA complex reveals a role for autoinhibition in maintenance DNA methylation. Science. 2011;331:1036–1040.
   PubMed Web of Science ®Google Scholar
• Lam JK, Chow MY, Zhang Y, et al. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
   PubMedGoogle Scholar
• First Affiliated Hospital of PLA General Hospital. Double-chain siRNA molecule of silencing DNMT gene and application. CN103757021. 2015.
   Google Scholar
• Teitell M, Richardson B. Dna methylation in the immune system. Clin Immunol. 2003;109:2–5.
   PubMed Web of Science ®Google Scholar
• Guo ZS, Hong JA, Irvine KR, et al. De novo induction of a cancer/testis antigen by 5-aza-2’-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res. 2006;66:1105–1113.
   PubMed Web of Science ®Google Scholar
• Cowan LA, Talwar S, Yang AS. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors. Epigenomics. 2010;2:71–86.
   PubMed Web of Science ®Google Scholar
• Christman JK. 5-azacytidine and 5-aza-2’-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21:5483–5495.
   PubMed Web of Science ®Google Scholar
• Konkuk University. Composition for regenerating damage by infection of HBV comprising DNA methyltransferase inhibitor. KR2014097894. 2014.
   Google Scholar
• Fan H, Lu X, Wang X, et al. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. J Immunol Res. 2014;2014:371087.
   PubMedGoogle Scholar
• Newman EM, Morgan RJ, Kummar S, et al. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2’-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015;75:537–546.
   PubMed Web of Science ®Google Scholar
• Plummer R, Vidal L, Griffin M, et al. Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin Cancer Res. 2009;15:3177–3183.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Donehower RC, Eisenhauer EA, et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol. 2003;14:766–774.
   PubMed Web of Science ®Google Scholar
• Davis AJ, Gelmon KA, Siu LL, et al. Phase I and pharmacologic study of the human DNA methyltransferase antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks. Invest New Drugs. 2003;21:85–97.
   PubMed Web of Science ®Google Scholar
• Kumar S, Horton JR, Jones GD, et al. DNA containing 4’-thio-2’-deoxycytidine inhibits methylation by HhaI methyltransferase. Nucleic Acids Res. 1997;25:2773–2783.
   PubMed Web of Science ®Google Scholar
• Thottassery JV, Sambandam V, Allan PW, et al. Novel DNA methyltransferase-1 (DNMT1) depleting anticancer nucleosides, 4’-thio-2’-deoxycytidine and 5-aza-4’-thio-2’-deoxycytidine. Cancer Chemother Pharmacol. 2014;74:291–302.
   PubMed Web of Science ®Google Scholar
• Phase I trial of 4’-Thio-2’-Deoxycytidine (TdCyd) in patients with advanced solid tumors (NCT02423057). clinicaltrials.gov; 2015 [cited 2016 Feb 16]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02423057?term=DNMT&rank=1.
   Google Scholar
• Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635–1640.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52–57.
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y, Sekeres M, Advani A, et al. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest. 2015;125:1043–1055.
   PubMed Web of Science ®Google Scholar
• Ahrens TD, Timme S, Hoeppner J, et al. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and azacytidine. Epigenetics. 2015;10:431–445.
   PubMed Web of Science ®Google Scholar
• Xia C, Leon-Ferre R, Laux D, et al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol. 2014;74:691–697.
   PubMed Web of Science ®Google Scholar
• Candelaria M, Herrera A, Labardini J, et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol. 2011;90:379–387.
   PubMed Web of Science ®Google Scholar
• INSERM; Universite de Montpellier; Centre Hospitalier Universitaire de Montpellier. Methods for predicting response to HDACi/DNMTi combination in multiple myeloma. WO2015140321. 2015.
   Google Scholar
• The Johns Hopkins University. Use of N1,N4-bis[3-(ethylamino)propyl]-2-butene-1,4-diamine compounds in combination with epigenetic-acting pharmaceuticals for enhanced cancer therapy. US2013102556. 2013.
   Google Scholar
• Georgetown University. Reversal of high breast cancer risk in mammals exposed to estrogenic chemicals in utero by adult exposure to HDAC and DNMT inhibitors. US2013324543. 2013.
   Google Scholar
• Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther. 2008;33:219–226.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2012;26:893–901.
   PubMed Web of Science ®Google Scholar
• Narayan R, Garcia JS, Percival MM, et al. Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome. Leuk Lymphoma. 2016;57:609–615.
   PubMed Web of Science ®Google Scholar
• Telik, Inc. Compositions and methods for treating myelodysplastic syndrome. WO2013019220. 2013
   Google Scholar
• Blum W, Schwind S, Tarighat SS, et al. Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood. 2012;119:6025–6031.
   PubMed Web of Science ®Google Scholar
• Walker AR, Klisovic RB, Garzon R, et al. Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2014;55:1304–1308.
   PubMed Web of Science ®Google Scholar
• Adams J, Kauffman M. Development of the proteasome inhibitor velcade™ (bortezomib). Cancer Invest. 2009;22:304–311.
   Web of Science ®Google Scholar
• A pilot study of pacritinib in combination with low dose decitabine in patients with intermediate-high risk myelofibrosis or MPN/MDS syndromes (NCT02564536). clinicaltrials.gov; 2015 [cited 2016 Feb 17]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02564536?term=DNMT&rank=13.
   Google Scholar
• Derenzini E, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. Expert Opin Investig Drugs. 2013;22:775–785.
   PubMed Web of Science ®Google Scholar
• Cyclacel Limited. Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine. US2014100187. 2014
   Google Scholar
• Palacký University Olomouc. Method of predicting the tumor response to DNA methylation inhibitors and alternative therapeutic regimen for overcoming resistance. WO2015144102 .2015.
   Google Scholar
• Coral S, Sigalotti L, Altomonte M, et al. 5-aza-2’-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res. 2002;8:2690–2695.
   PubMed Web of Science ®Google Scholar
• Saleh MH, Wang L, Goldberg MS. Improving cancer immunotherapy with DNA methyltransferase inhibitors. Cancer Immunol Immunother. 2016;65:787–796.
   PubMed Web of Science ®Google Scholar
• Li H, Chiappinelli KB, Guzzetta AA, et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 2014;5:587–598.
   PubMed Web of Science ®Google Scholar
• Epner E, Saroya BS, Hasanali Z, et al. Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: a new therapeutic approach. Exp Hematol. 2016;44:157–160.
   PubMed Web of Science ®Google Scholar
• Weintraub K. Take two: combining immunotherapy with epigenetic drugs to tackle cancer. Nat Med. 2016;22:8–10.
   PubMed Web of Science ®Google Scholar
• Combination of oral THU-decitabine with nivolumab for treatment of patients with advanced non-small cell lung cancer (NCT02664181). clinicaltrials.gov; 2016 [cited 2016 Feb 17]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02664181?term=DNMT&rank=10.
   Google Scholar
• Garrido-Laguna I, McGregor KA, Wade M, et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest New Drugs. 2013;31:1257–1264.
   PubMed Web of Science ®Google Scholar
• Wahnon DC, Shier VK, Benkovic SJ. Mechanism-based inhibition of an essential bacterial adenine DNA methyltransferase: rationally designed antibiotics. J Am Chem Soc. 2001;123:976–977.
   PubMed Web of Science ®Google Scholar
• Rondelet G, Dal Maso T, Willems L, et al. Structural basis for recognition of histone H3K36me3 nucleosome by human de novo DNA methyltransferases 3A and 3B. J Struct Biol. 2016;194:357–367.
   PubMed Web of Science ®Google Scholar
• Cheng J, Yang H, Fang J, et al. Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation. Nat Commun. 2015;6:7023.
   PubMed Web of Science ®Google Scholar
• Guo X, Wang L, Li J, et al. Structural insight into autoinhibition and histone H3-induced activation of DNMT3A. Nature. 2015;517:640–644.
   Web of Science ®Google Scholar
• Chang Y, Sun L, Kokura K, et al. MPP8 mediates the interactions between DNA methyltransferase Dnmt3a and H3K9 methyltransferase GLP/G9a. Nat Commun. 2011;2:533.
   PubMed Web of Science ®Google Scholar
• Song J, Teplova M, Ishibe-Murakami S, et al. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science. 2012;335:709–712.
   PubMed Web of Science ®Google Scholar
• Jin L, Ye F, Zhao D, et al. Metadynamics simulation study on the conformational transformation of HhaI methyltransferase: an induced-fit base-flipping hypothesis. Biomed Res Int. 2014;2014:304563.
   PubMedGoogle Scholar
• Yoo J, Choi S, Medina-Franco JL. Molecular modeling studies of the novel inhibitors of DNA methyltransferases SGI-1027 and CBC12: implications for the mechanism of inhibition of DNMTs. PLoS One. 2013;8:e62152.
   PubMed Web of Science ®Google Scholar
• Hauser AT, Jung M. Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Med. 2008;74:1593–1601.
   PubMed Web of Science ®Google Scholar
• Li Y, Saldanha SN, Tollefsbol TO. Impact of epigenetic dietary compounds on transgenerational prevention of human diseases. Aaps J. 2014;16:27–36.
   PubMed Web of Science ®Google Scholar